Imputation

NRGene and Agriplex Genomics Announce Mutual Collaboration for Mid-density Genotyping Services

Retrieved on: 
Tuesday, October 20, 2020
Health, Technology, Other Technology, Genetics, Agriculture, Natural Resources, Branches of biology, Biology, Molecular biology, DNA, Biotechnology, Statistical genetics, Genetics, Imputation, Genotyping, Single-nucleotide polymorphism, NRGene, Agriplex Genomics

NRGene and Agriplex Genomics are pleased to announce a non-exclusive collaboration to provide end-to-end optimized mid-density genotyping services.

Key Points: 
  • NRGene and Agriplex Genomics are pleased to announce a non-exclusive collaboration to provide end-to-end optimized mid-density genotyping services.
  • This new collaboration couples NRGenes new software solution for optimized genotyping with Agriplexs amplicon-based technology to offer the breeding community a complete end-to-end solution for low-cost genotyping.
  • Together with Agriplex, we successfully combined customized genotyping set design, low cost genotyping services and accurate imputation, thus providing breeders with more knowledge at significantly lower costs.
  • AgriPlex Genomics specializes in focused, simultaneous NGS analysis of a flexible number of SNPs across thousands of samples.

Benefitfocus Delivers Enhanced Mobile and Communications Capabilities

Retrieved on: 
Thursday, May 21, 2020
Taxation in the United States, Imputed income, Income taxation, Tax reform, Economy, Imputation, Forward-looking statement, Tax, Articles

"Our goal with each release is to improve the customer experience for our consumers, employers, brokers and health plans," said Benefitfocus CTO Jim Restivo.

Key Points: 
  • "Our goal with each release is to improve the customer experience for our consumers, employers, brokers and health plans," said Benefitfocus CTO Jim Restivo.
  • These enhancements are the latest results of Benefitfocus' goal to provide a world-class data experience for all members of its platform.
  • Expanded Imputed Income Calculation Capabilities Our imputed income configurations have been expanded to include child and dependent life benefits.
  • Benefitfocus assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Macrogen: Successful Construction of the Largest Northeast Asian Reference Panel

Retrieved on: 
Monday, December 2, 2019
Science, Biotechnology, Research, Health, Data management, Hospitals, Technology, Genetics, Branches of biology, Biology, Genetic epidemiology, Genome-wide association study, Genomics, Statistical genetics, Bioinformatics, Genetics, Imputation, Computational and Statistical Genetics

In addition, NARD can provide higher level of accuracy in terms of Northeast Asian genome analysis than other existing reference panels around the world.

Key Points: 
  • In addition, NARD can provide higher level of accuracy in terms of Northeast Asian genome analysis than other existing reference panels around the world.
  • The panel constructed from the Haplotype Reference Consortium, which has been known as the largest publicly available reference panel in the world, comprises mostly European races, but only 1% of Northeast Asian genome data has been included.
  • This lack of data makes it hard to obtain high accuracy when conducting genome-wide association study (GWAS) for Northeast Asians, thus the need to compile a large Northeast Asian reference panel has been highlighted.
  • He added, We will release a second Northeast Asian reference panel from 10,000 individuals early next year.

Gencove launches the first enterprise-ready low-pass sequencing imputation and analysis software as a service

Retrieved on: 
Tuesday, October 15, 2019
Branches of biology, Biology, Molecular biology, Life sciences, Biotechnology, DNA, Genomics, Whole genome sequencing, Imputation, DNA sequencing, Sequencing

NEW YORK, Oct. 15, 2019 /PRNewswire/ -- Gencove, the leading low-pass genome sequencing technology provider, announced today the launch of the first enterprise-ready low-pass sequencing analysis platform.

Key Points: 
  • NEW YORK, Oct. 15, 2019 /PRNewswire/ -- Gencove, the leading low-pass genome sequencing technology provider, announced today the launch of the first enterprise-ready low-pass sequencing analysis platform.
  • The new cloud-based solution for imputation and downstream analytics of low-pass sequencing data is an important step forward in expanding the access to this technology.
  • For the last two years, Gencove has successfully helped organizations across industries from academia to agriculture switch from genotyping arrays to sequencing technologies.
  • Gencove's SaaS also provides additional analysis on top of low-pass data, like polygenic risk score calculations, ancestry/breed analysis and CNV analysis.

seqWell and Gencove partner to offer a low-pass whole genome sequencing end-to-end solution

Retrieved on: 
Thursday, January 31, 2019
Branches of biology, Biology, Molecular biology, DNA, Biotechnology, Bioinformatics, Imputation, Genotyping, DNA sequencing, Whole genome sequencing, Exome sequencing, Computational and Statistical Genetics

and NEW YORK, Jan. 31, 2019 /PRNewswire/ -- seqWell and Gencove today announced a partnership to bring together seqWell's plexWell library preparation technology and Gencove's imputation and analysis software to provide genomic researchers a powerful and scalable end-to-end solution for low-pass whole genome sequencing and genotype imputation.

Key Points: 
  • and NEW YORK, Jan. 31, 2019 /PRNewswire/ -- seqWell and Gencove today announced a partnership to bring together seqWell's plexWell library preparation technology and Gencove's imputation and analysis software to provide genomic researchers a powerful and scalable end-to-end solution for low-pass whole genome sequencing and genotype imputation.
  • Gencove is the industry pioneer in low-pass sequencing technologies.
  • This technology offers a high-throughput, cost-efficient and accurate solution for large-scale genomic projects that historically have relied on genotyping microarrays.
  • plexWell technology from seqWell overcomes challenges of library preparation workflow scalability through massively paralleled multiplexing of samples.

Study Supports Alternative Method for Estimating Treatment Effects in Clinical Trials

Retrieved on: 
Tuesday, October 23, 2018
Health, Clinical research, Medical research, Design of experiments, Medicine, Clinical trials, Epidemiology, Cutaneous lupus erythematosus, Systemic lupus erythematosus, Imputation, Analysis of clinical trials

This may be due to patients dropping out or missing follow up appointments in clinical trials.

Key Points: 
  • This may be due to patients dropping out or missing follow up appointments in clinical trials.
  • One missing data method, called multiple imputation (MI), has been used in other disease areas successfully, and the current study shows the potential advantages of this method in evaluating treatment effects in lupus trials using data from the LFA-Collective Data Analysis Initiative (CDAI).
  • In the research abstract, Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects , Dr. Kim analyzed data on 279 patients with lupus who took part in a study for 52 weeks.
  • The study showed how trial conclusions can change depending on the method used to address missing data.